Vericel Corp Ord (VCEL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.91B
Last updated: Nov 17, 2026 at 11:05 AM ET
Vericel Corp Ord (VCEL) Financials: Revenue, Profit and Cash Flow
Vericel Corp Ord reported revenue of $276.26M for the fiscal year ended Dec 31, 2025, up 16.5% from the year before. That year, net income was $16.52M with a net margin of 6.0%, operating cash flow was $51.91M and free cash flow was $24.75M. The quarter ended Sep 30, 2026 had revenue of $85.37M and net income of $14.16M.
Revenue and Margins
The operating margin was 4.0% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $54.38M, a compound annual rate of 19.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $276.26M | +16.5% | 74.4% | 4.0% | 6.0% |
| Dec 2024 | $237.22M | +20.1% | 72.6% | 1.9% | 4.4% |
| Dec 2023 | $197.52M | +20.2% | 68.6% | -3.3% | -1.6% |
| Dec 2022 | $164.37M | +5.2% | 66.8% | -10.4% | -10.2% |
| Dec 2021 | $156.18M | +25.8% | 67.9% | -5.0% | -4.8% |
| Dec 2020 | $124.18M | +5.4% | 67.8% | 1.9% | 2.3% |
| Dec 2019 | $117.85M | +29.7% | 68.1% | -9.5% | -8.2% |
| Dec 2018 | $90.86M | +42.1% | 64.6% | -4.3% | -9.0% |
| Dec 2017 | $63.92M | +17.5% | 52.5% | -23.4% | -27.0% |
| Dec 2016 | $54.38M | N/A | 47.9% | -35.4% | -36.0% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 59.5% from the year before. In the quarter ended Sep 2026, net income rose 179.3% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $276.26M | $237.22M | $197.52M | $164.37M | $156.18M | $124.18M | $117.85M | $90.86M | $63.92M | $54.38M |
| Cost of revenue | $70.66M | $65.12M | $61.94M | $54.58M | $50.16M | $39.95M | $37.57M | $32.16M | $30.35M | $28.31M |
| Gross profit | $205.60M | $172.11M | $135.58M | $109.79M | $106.03M | $84.23M | $80.28M | $58.70M | $33.57M | $26.08M |
| Research and development | $27.56M | $24.80M | $21.04M | $19.94M | $16.29M | $13.02M | $30.39M | $13.60M | $12.94M | $15.29M |
| Operating income | $11.04M | $4.52M | -$6.46M | -$17.06M | -$7.85M | $2.37M | -$11.25M | -$3.91M | -$14.98M | -$19.25M |
| Net income | $16.52M | $10.36M | -$3.18M | -$16.71M | -$7.47M | $2.86M | -$9.66M | -$8.14M | -$17.29M | -$19.57M |
| EBITDA | $22.58M | $9.78M | -$2.38M | -$12.79M | -$3.89M | $5.06M | -$10.14M | N/A | -$14.74M | -$17.67M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $85.37M | $77.46M | $68.42M | $92.92M | $67.50M | $63.24M | $52.60M | $75.38M | $57.91M | $52.66M | $51.28M | $65.00M |
| Gross profit | $62.61M | $56.40M | $49.27M | $73.13M | $49.59M | $46.61M | $36.27M | $58.50M | $41.65M | $36.60M | $35.35M | $48.51M |
| Operating income | $12.19M | $434.00K | -$8.06M | $22.41M | $3.45M | -$2.03M | -$12.79M | $18.48M | -$2.46M | -$6.03M | -$5.46M | $12.73M |
| Net income | $14.16M | $2.21M | -$6.30M | $23.24M | $5.07M | -$553.00K | -$11.25M | $19.81M | -$901.00K | -$4.68M | -$3.86M | $12.99M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $14.09M by $86.01M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $487.97M | $432.72M | $353.66M | $273.00M | $243.71M | $205.61M | $153.24M | $118.69M | $54.58M | $48.60M |
| Current assets | $247.44M | $212.78M | $205.63M | $186.87M | $158.46M | $123.56M | $111.66M | $112.78M | $50.51M | $44.72M |
| Cash and equivalents | $100.09M | $74.52M | $69.09M | $51.07M | $68.33M | $33.62M | $26.89M | $18.29M | $26.86M | $22.98M |
| Total liabilities | $133.33M | $140.75M | $127.70M | $80.73M | $73.24M | $71.35M | $42.15M | $16.46M | $32.04M | $23.89M |
| Short-term debt | $14.09M | $9.26M | $6.19M | $4.30M | $2.99M | $4.43M | $5.50M | N/A | $350.00K | $779.00K |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $16.89M | $32.00K |
| Shareholder equity | $354.64M | $291.97M | $225.95M | $192.27M | $170.46M | $134.26M | $111.09M | $102.23M | $22.54M | $24.71M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $517.11M | $502.87M | $485.63M | $487.97M | $453.27M | $435.61M | $424.59M | $432.72M | $390.40M | $376.84M | $356.66M | $353.66M |
| Total liabilities | $132.94M | $132.82M | $129.40M | $133.33M | $131.42M | $128.80M | $129.10M | $140.75M | $132.93M | $133.86M | $122.77M | $127.70M |
| Cash and equivalents | $133.49M | $125.36M | $109.30M | $100.09M | $100.40M | $80.53M | $73.49M | $74.52M | $53.68M | $50.29M | $62.94M | $69.09M |
| Shareholder equity | $384.17M | $370.04M | $356.23M | $354.64M | $321.86M | $306.81M | $295.49M | $291.97M | $257.47M | $242.98M | $233.90M | $225.95M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 47.7% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $51.91M | $58.16M | $35.31M | $17.69M | $29.04M | $17.57M | -$7.18M | -$412.00K | -$13.18M | -$19.89M |
| Capital expenditures | $27.16M | $63.97M | $20.01M | $7.60M | $7.92M | $2.63M | $2.62M | $2.68M | $1.51M | $1.42M |
| Free cash flow | $24.75M | -$5.81M | $15.30M | $10.09M | $21.13M | $14.95M | -$9.80M | -$3.09M | -$14.69M | -$21.31M |
| Investing cash flow | -$43.94M | -$79.03M | -$3.13M | -$36.21M | -$3.50M | -$17.16M | $10.62M | -$67.03M | -$1.51M | -$1.42M |
| Financing cash flow | $7.07M | $19.05M | $3.62M | $1.04M | $9.17M | $6.44M | $5.26M | $58.86M | $18.58M | $29.70M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $17.72M | $16.19M | $16.38M | $15.01M | $22.08M | $8.21M | $6.60M | $22.24M | $10.18M | $18.54M | $7.20M | $10.09M |
| Capital expenditures | $2.04M | $1.93M | $1.26M | $2.19M | $2.63M | $8.13M | $14.21M | $13.79M | $19.41M | $16.76M | $14.02M | $7.83M |
| Free cash flow | $15.68M | $14.26M | $15.13M | $12.83M | $19.45M | $81.00K | -$7.61M | $8.46M | -$9.22M | $1.77M | -$6.82M | $2.25M |
Frequently Asked Questions About VCEL
What is Vericel Corp Ord's annual revenue?
Vericel Corp Ord reported revenue of $276.26M for the fiscal year ended Dec 31, 2025.
How fast is Vericel Corp Ord's revenue growing?
Revenue was up 16.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 18.9%.
Is Vericel Corp Ord profitable?
Yes. Vericel Corp Ord reported net income of $16.52M for the fiscal year ended Dec 31, 2025, with a net margin of 6.0%.
How much free cash flow does VCEL generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $51.91M minus capital expenditures of $27.16M produced free cash flow of $24.75M.
How much debt does Vericel Corp Ord have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $14.09M and cash and equivalents of $100.09M.
VCEL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors